Tallimustine

Summary

Tallimustine is an investigational antineoplastic peptide that belongs to the distamycin‑derived minor‑groove binders. It is a benzoyl nitrogen‑mustard analogue designed to alkylate adenine residues in AT‑rich DNA sequences, thereby interfering with gene transcription. Early clinical trials evaluated it for solid tumours, but development was halted because of pronounced bone‑marrow toxicity and limited tumour responses.

Mechanism of Action

Tallimustine binds selectively to the minor groove of DNA at AT‑rich hexamer motifs (e.g., 5'-TTTTGA or 5'-TTTTAA). The attached benzoyl mustard moiety alkylates the N3 position of adenine within this groove, producing sequence‑specific DNA adducts that block transcription without causing classic strand breaks or interstrand cross‑links. This targeted alkylation is intended to yield cytotoxicity preferentially in tumour cells while sparing non‑target DNA.

What the Research Shows

Preclinical studies showed strong activity against a range of experimental tumours and no cross‑resistance with cyclophosphamide. Phase I trials in adults with solid malignancies identified neutropenia as the dose‑limiting toxicity; the maximal tolerated dose was 1250 µg/m2 as a single IV bolus every four weeks, and 200 µg/m2/day for three consecutive days every 28 days in a later study. Pharmacokinetic data revealed rapid plasma clearance and no accumulation over three days. A single partial response lasting four months was reported in a mesothelioma patient, but a phase II trial in previously treated small‑cell lung cancer (14 patients) showed no objective responses and only modest disease stabilisation. The overall clinical efficacy was deemed insufficient, and development was discontinued, prompting the search for less marrow‑toxic distamycin analogues such as brostallicin.

Reported Benefits

Tallimustine demonstrated sequence‑specific DNA alkylation, which may reduce off‑target effects compared with conventional, non‑selective alkylators. Preclinical models indicated broad antitumour activity, and a partial response in a mesothelioma patient suggested potential activity in selected tumour types. The drug’s rapid plasma clearance and lack of significant non‑hematologic toxicity were noted as favorable attributes.

Limitations of the Evidence

The primary limitation is severe, dose‑limiting neutropenia, with frequent febrile episodes at therapeutic doses. Clinical trials have not shown consistent tumour regressions; a phase II study in small‑cell lung cancer found it ineffective. Development ceased after early‑phase trials, and no regulatory approval has been granted. Evidence of benefit is limited to small, uncontrolled studies, and the therapeutic index remains unfavourable.

Safety Considerations

Neutropenia is the principal adverse effect, often grade 3‑4 and sometimes accompanied by febrile neutropenia requiring antibiotics. One death of indeterminate cause occurred in a phase I study. Thrombocytopenia and severe anemia were uncommon, while occasional transient elevations of liver enzymes or bilirubin were observed but not dose‑related. Bone‑marrow suppression appears highly selective for the myeloid lineage with rapid recovery after drug clearance. Close hematologic monitoring and supportive care are essential when the drug is administered.

How It Is Administered

Tallimustine is supplied for intravenous administration. Clinical protocols have used a single IV bolus every four weeks or a three‑day consecutive IV infusion schedule repeated every 28 days. Dosing is expressed in micrograms per square metre of body‑surface area. Formulations are aqueous solutions suitable for infusion.

Routes of Administration

Goals & Uses

• Solid tumor treatmentOncologyLow
• Sequence-selective DNA alkylation researchResearchModerate
• Hematologic malignancy treatmentOncologyLow

Contraindications

• Severe hepatic impairmentOrganModerateLiver function concerns
• Pre-existing severe bone marrow suppressionHematologicHigh
• Severe renal impairmentOrganModerateKidney function concerns
• PregnancyPopulationHighPotential fetal risk or insufficient safety data

Adverse Effects

• HepatotoxicityHepaticUncommonLiver injury or dysfunction
• AlopeciaDermatologicUncommonHair loss
• Nausea and vomitingGastrointestinalCommon
• MucositisGastrointestinal / MucosalUncommon
• Myelosuppression (neutropenia, thrombocytopenia)HematologicCommon
• Fatigue/astheniaGeneralCommon

Drug Interactions

• Live attenuated vaccinesHigh
• Other myelosuppressive agentsHigh

Population Constraints

• Pediatric patientsAgeRelative
• Pregnant or breastfeeding womenReproductiveAbsolute
• Elderly patientsAgeRelative

Regulatory Status

• European UnionInvestigationalClinical trials conducted in European centers; no marketing authorization ever granted.
• United StatesInvestigationalStudied under IND in Phase I/II trials; never approved by FDA.
• United KingdomInvestigationalNo approval; remained investigational only.

Never received regulatory approval in any jurisdiction. Investigated under clinical trial frameworks in Europe and the United States. Development was discontinued; no approved indications exist.

Evidence & Sources

• Phase I study of the novel distamycin derivative tallimustine (FCE 24517)
  Journal ArticleModerateSessa C, et al.1994-01-01T00:00:00.000000Z
• A phase I and pharmacokinetic study of tallimustine [PNU 152241 (FCE 24517)] in patients with advanced cancer
  Journal ArticleModerateWeiss GR, et al.1998-01-01T00:00:00.000000Z
• Tallimustine is inactive in patients with previously treated small cell lung cancer. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group
  Journal ArticleModerateViallet J, et al.1996-01-01T00:00:00.000000Z
• Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests
  Journal ArticleModerateParchment RE, et al.1998-01-01T00:00:00.000000Z
• Development of distamycin-related DNA binding anticancer drugs
  Journal ArticleModerateMarchini S, et al.2001-01-01T00:00:00.000000Z
• Cytotoxics derived from distamycin A and congeners
  Journal ArticleModerateCozzi P, Mongelli N1998-01-01T00:00:00.000000Z

Frequently Asked Questions